Filing Flows › Silence Therapeutics (SLN) › Q2 2025
Silence Therapeutics (SLN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Silence Therapeutics (SLN) reported revenue of $224K for the second quarter 2025 (Q2 2025), -70% from a year earlier and +58% from the quarter before.
Silence Therapeutics, Q2 2025: revenue $224K (-70% year over year), net loss $27.4M, operating cash flow −$21.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $224K | +58% | -70% |
| Operating profit | −$24.0M | — | — |
| Net earnings | −$27.4M | — | — |
| Operating cash flow | −$21.8M | — | — |
What changed
Revenue was $224K in Q2 2025, down 70% year over year and up 58% from the previous quarter.
Gross margin was 62.1%. Operating costs exceeded revenue by $24.0M, an operating margin of -10697.8%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $27.4M, narrower than the previous quarter's $28.5M loss.
Operating cash flow was −$21.8M. Non-cash charges added back $81K of depreciation and $2.1M of share-based compensation. Working capital and other items added $3.4M. Capital expenditures of $48K exceeded it, leaving free cash flow of −$21.8M.
Questions
What was Silence Therapeutics' revenue in the second quarter 2025?
Silence Therapeutics (SLN) reported revenue of $224K for the second quarter 2025 (Q2 2025), -70% from a year earlier and +58% from the quarter before.